logo

For the Inventor, By the Inventor

Vienna, Austria

Peter Stutz

USPTO Granted Patents = 12

Average Co-Inventor Count = 2.7

ph-index = 7

Forward Citations = 81(Granted Patents)


Location History:

  • Bottmingen, CH (1979 - 1982)
  • Vienna, AT (1978 - 1997)

Company Filing History:

goldMedal12 out of 1,603 
 
Sandoz Gmbh
 patents

Years Active: 1978-1997

Loading Chart...
12 patents (USPTO):Explore Patents
1. 5665727 - Use of 11,28-dioxa-4-azatricyclo[22.3.1.0.sup.4,9 ]octacos-18-ene (1997-09-09),
2. 5366971 - Use of 11,28-dioxa-4-azatricyclo[22.3.1.0.sup.4,9 ]octacos-18-ene (1994-11-22),
3. 5210072 - Muramyl dipeptide derivatives (1993-05-11),
4. 4783464 - N-substituted ergoline- and (1988-11-08),
5. 4680291 - Propenylamines, processes for their production and pharmaceutical (1987-07-14),
6. 4547500 - Ergot peptide derivatives, their preparation and pharmaceutical (1985-10-15),
7. 4348392 - 8.alpha.-Substituted ergoline-I derivatives (1982-09-07),
8. 4348391 - Sulfonamido and sulfamoylamino-ergoline-I derivatives (1982-09-07),
9. 4320133 - Penicillins and their antibacterial use (1982-03-16),
10. 4147789 - 6-Methyl-8-thiomethyl-ergolene derivatives (1979-04-03),
11. 4146626 - 8-Adamantylaminomethyl ergolene derivatives (1979-03-27),
12. 4124712 - Ergot peptide alkaloid derivatives (1978-11-07),

Title: Innovations of Peter Stutz

Introduction

Peter Stutz is a notable inventor based in Vienna, Austria. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of skin diseases. With a total of 12 patents to his name, Stutz has demonstrated a commitment to advancing medical science.

Latest Patents

Among his latest patents is the use of 11,28-dioxa-4-azatricyclo[22.3.1.0.sup.4,9]octacos-18-ene. This compound has been found to exhibit excellent topical activity, making it suitable for the treatment of inflammatory and hyperproliferative skin diseases. Additionally, he has patented new uses of 11,28-dioxa-4-azatricyclo[22.3.1.0.sup.4,9]octacos-18-ene derivatives and pharmaceutical compositions containing them. These innovations are particularly indicated for addressing cutaneous manifestations of immunologically-induced illnesses, such as psoriasis.

Career Highlights

Peter Stutz is currently associated with Sandoz GmbH, where he continues to work on groundbreaking pharmaceutical developments. His expertise in the field has led to numerous advancements that benefit patients suffering from various skin conditions.

Collaborations

Stutz has collaborated with notable colleagues, including Paul A. Stadler and Anton Stutz. These partnerships have fostered a collaborative environment that enhances the innovation process.

Conclusion

Peter Stutz is a prominent figure in the pharmaceutical industry, known for his innovative patents and contributions to medical science. His work continues to impact the treatment of skin diseases positively.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…